© 2007

Entry Inhibitors in HIV Therapy

  • Jacqueline D. Reeves
  • Cynthia A. Derdeyn

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages I-X
  2. Laurence Vergne, Martine Peeters
    Pages 17-29
  3. Stefan Pöhlmann, Michel J. Tremblay
    Pages 31-47
  4. Pin-fang Lin, John Kadow, Louis Alexander
    Pages 49-62
  5. Julie M. Strizki, Donald E. Mosier
    Pages 63-78
  6. Wei Wang, Carol D. Weiss
    Pages 79-97
  7. Clyde E. Hart, Tammy Evans-Strickfaden
    Pages 99-117
  8. Lynn Morris, Mia Coetzer, Elin S. Gray, Tonie Cilliers, Kabamba B. Alexandre, Penny L. Moore et al.
    Pages 119-131
  9. Sonya L. Heath, J. Michael Kilby
    Pages 145-160
  10. Michael L. Greenberg
    Pages 161-177
  11. Back Matter
    Pages 197-200

About this book


Entry Inhibitors in HIV Therapy presents the current status of this relatively new and highly dynamic class of inhibitors and provides a unique overview of obstacles and considerations for HIV entry inhibition compared to other antiretroviral targets.

The introductory chapters of this book present an overview of entry inhibitors, review current knowledge of how Env mediates entry, and discuss the challenge of genetic diversity in this region of the viral genome. Subsequent chapters feature current information on individual classes of entry inhibitors that target each step of the virus entry pathway, from attachment to membrane fusion. There is an emphasis on the complex determinants of entry inhibitor susceptibility, resistance mechanisms, the need for clinical phenotyping, and how these issues create new challenges for antiretroviral therapy. Encouraging pre-clinical studies of entry inhibitors as microbicidesare also discussed. The final chapters highlight the current status of entry inhibitors in clinical studies, the major milestone achieved with FDA approval of enfuvirtide, and review drug development, past and present.

In summary, this book presents a comprehensive and current overview of entry inhibitors from an expert panel of authors with diverse backgrounds and perspectives, incorporating many unrelenting successes against a backdrop of formidable challenges. It is of interest to basic science researchers as well as clinical physicians.


AIDS HIV HIV Therapy HIV infection development drug drug development glycoprotein immunodeficiency immunology infection protein proteins research virus

Editors and affiliations

  • Jacqueline D. Reeves
    • 1
  • Cynthia A. Derdeyn
    • 2
  1. 1.Monogram BiosciencesSouth San FranciscoUSA
  2. 2.Department of Pathology and Laboratory Medicine, Emory Vaccine CenterEmory UniversityAtlantaUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods